Sickle Cell News
Timely updates, research breakthroughs, and policy changes that matter to Oklahoma families living with sickle cell.
Sickle Cell News & Information
Access current news, research findings, and educational updates related to Sickle Cell Disease. Our goal is to share accurate, relevant information that supports informed decision-making and ongoing awareness.
Winter in Oklahoma: A Sickle Cell “Stay-Ready” Plan for Cold Weather, School, and ER Visits
Why winter can be harder with SCD Cold exposure can contribute to pain episodes for many people with sickle cell. Winter also adds: school schedule disruptions, respiratory illness spikes, holiday travel, and weather-related access issues. A practical winter checklist...
Trial News: A High-Profile Sickle Cell Drug Study Missed Its Goal—What That Means for the Community
In August 2025, Reuters reported that Pfizer’s experimental sickle cell drug inclacumab failed to meet its main goal in a late-stage study (no significant difference in vaso-occlusive crisis frequency vs placebo). Reuters Why this still matters When a trial fails, it...
Oklahoma Spotlight: What a 2025 SoonerCare Report Says About Sickle Cell Care (and Why It Matters)
In January 2025, the Oklahoma Health Care Authority published an annual update evaluating how SoonerCare serves members with sickle cell disease—an ongoing effort tied to state legislative requirements. Welcome to Oklahoma's Official Web Site The key point: Oklahoma...
Medication Update: What the Voxelotor (Oxbryta) Withdrawal Means Now—and What Research Is Saying
In late 2024, Pfizer withdrew voxelotor (Oxbryta) from the market globally after concluding the risks outweighed the benefits. ASH Research Collaborative+1That decision hit patients and clinicians hard—because many people had built their routine around it. New...
Big News: Gene Therapy for Younger Kids Is Showing Promise (What Oklahoma Families Should Know)
If you’ve been following gene therapy for sickle cell disease (SCD), you’ve probably heard about Casgevy (exa-cel)—a CRISPR-based gene-editing therapy currently approved for some patients ages 12+. In early December 2025, Vertex reported that children ages 5–11 in a...